Liver Transplantation
Liver transplant recipients face graft rejection with interferon-based therapy
Published in Hepatitis Weekly, September 6th, 2004
According to a study from the United States, "recurrent hepatitis C after liver transplantation remains a significant cause of graft loss and retransplantation. Although treatment of recurrent hepatitis C with interferon-based regimens has become widely accepted as safe and can lead to sustained virologic clearance of hepatitis C virus (HCV) RNA, long-term histologic improvement and the risk of precipitating graft rejection remain controversial."
"The present study is a retrospective evaluation of the clinical and histological consequences of treating recurrent hepatitis...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-09-06)
More Articles from Hepatitis Weekly
- Chronic Liver Disease
Non-invasive elastometry is a valuable tool for staging liver fibrosis - Immunology
Interferon-gamma signals slow progression in hepatitis C-infected patients - Immunosuppression
Rapid steroid withdrawal is appropriate for HCV-positive kidney recipients - Transplant Medicine
Race affects the outcomes of patients awaiting liver transplantations - Viral Epidemiology
A new assay distinguishes hepatitis B virus genotype A subtypes - AIDS/HIV Vaccine
Hemagglutinating virus protein induces immune response with HIV vaccine - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
